PE20030581A1 - Composiciones polimeras de liberacion controlada de compuestos que promueven el crecimiento oseo - Google Patents

Composiciones polimeras de liberacion controlada de compuestos que promueven el crecimiento oseo

Info

Publication number
PE20030581A1
PE20030581A1 PE2002001144A PE2002001144A PE20030581A1 PE 20030581 A1 PE20030581 A1 PE 20030581A1 PE 2002001144 A PE2002001144 A PE 2002001144A PE 2002001144 A PE2002001144 A PE 2002001144A PE 20030581 A1 PE20030581 A1 PE 20030581A1
Authority
PE
Peru
Prior art keywords
compounds
controlled release
polymer compositions
bone growth
mga
Prior art date
Application number
PE2002001144A
Other languages
English (en)
Inventor
Mei Li
Vishwas Madhav Paralkar
Richard Wilker Korsmeyer
Scott Alexander Jeffers
Mingxing Zhou
Richard Lee Dunn
Francis Dumont
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20030581A1 publication Critical patent/PE20030581A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

QUE COMPRENDE: 1)UN POLIMERO O COPOLIMERO TERMOPLASTICO, BIODEGRADABLE FARMACEUTICAMENTE ACEPTABLE QUE ES INSOLUBLE EN FLUIDO ACUOSO O CORPORAL, SELECCIONADO DE: POLILACTIDOS, POLIGLICOLIDOS Y COPOLIMEROS DE LOS MISMOS, TAL COMO POLI(ACIDO LACTICO-CO-GLICOLICO) (PLGH); 2)UN DISOLVENTE ORGANICO BIOCOMPATIBLE QUE SOLUBILIZA A (1), DISPERSABLE IN SITU EN FLUIDO CORPORAL, MUY SOLUBLE EN AGUA Y CAPAZ DE DISIPARSE DEL SISTEMA DE POLIMERO EN FLUIDO DE TEJIDO CIRCUNDANTE DE MANERA QUE (1) FORMA EL IMPLANTE; 3)APROXIMADAMENTE ENTRE 5 mgA/ml Y 50 mgA/ml DE UN COMPUESTO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, SELECCIONADA DE: ACIDO (3-(((4-TERC-BUTILBENCIL)-(PIRIDIN-3-SULFONIL)AMINO)METIL)FENOXI)ACETICO; ACIDO 7-[(4-BUTILBENCIL)METANOSULFONILAMINO)HEPTANOICO; Y ACIDO 7-{[2-(3,5-DICLOROFENOXI)ETIL]METASULFONILAMINO}HEPTANOICO. DONDE (2) ES N-METIL-2-PIRROLIDONA (NMP) Y EL PORCENTAJE EN PESO DE PLGH A NMP EN SOLUCION SE ENCUENTRA ENTRE 30% Y 60%. SE REFIERE TAMBIEN A UN METODO PARA FORMAR UN IMPLANTE IN SITU EN UN CUERPO VIVO
PE2002001144A 2001-11-30 2002-11-27 Composiciones polimeras de liberacion controlada de compuestos que promueven el crecimiento oseo PE20030581A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33725501P 2001-11-30 2001-11-30

Publications (1)

Publication Number Publication Date
PE20030581A1 true PE20030581A1 (es) 2003-07-08

Family

ID=23319774

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001144A PE20030581A1 (es) 2001-11-30 2002-11-27 Composiciones polimeras de liberacion controlada de compuestos que promueven el crecimiento oseo

Country Status (34)

Country Link
US (2) US20030104031A1 (es)
EP (1) EP1448166A1 (es)
JP (1) JP4903985B2 (es)
KR (1) KR100629380B1 (es)
CN (1) CN1599598A (es)
AP (1) AP1781A (es)
AR (1) AR037462A1 (es)
AU (2) AU2002347502A1 (es)
BR (1) BR0214610A (es)
CA (1) CA2468703C (es)
DO (1) DOP2002000534A (es)
EA (1) EA011350B1 (es)
EC (1) ECSP045124A (es)
GE (1) GEP20063951B (es)
GT (1) GT200200242A (es)
HR (1) HRP20040486A2 (es)
HU (1) HUP0402135A3 (es)
IL (1) IL161835A0 (es)
IS (1) IS7217A (es)
MA (1) MA27084A1 (es)
MX (1) MXPA04003723A (es)
NO (1) NO20042273L (es)
NZ (1) NZ533115A (es)
OA (1) OA12731A (es)
PA (1) PA8559001A1 (es)
PE (1) PE20030581A1 (es)
PL (1) PL370085A1 (es)
SV (1) SV2004001421A (es)
TN (1) TNSN04096A1 (es)
TW (1) TW200300695A (es)
UA (1) UA76792C2 (es)
WO (1) WO2003045351A1 (es)
YU (1) YU35004A (es)
ZA (1) ZA200402755B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074425B2 (en) * 2002-09-26 2006-07-11 Bonewax, Llc Hemostatic compositions and methods
WO2004071356A2 (en) * 2003-02-10 2004-08-26 Smith & Nephew, Inc. Resorbable devices
GB0307011D0 (en) 2003-03-27 2003-04-30 Regentec Ltd Porous matrix
CA2540586A1 (en) * 2003-10-01 2005-04-21 Optimer Pharmaceuticals, Inc. Treatment of a condition in a mammal with administration of aminosugar and uses thereof
GB0329654D0 (en) 2003-12-23 2004-01-28 Smith & Nephew Tunable segmented polyacetal
US8123787B2 (en) 2004-10-28 2012-02-28 Ogilvie James W Method of treating scoliosis using a biological implant
US8641738B1 (en) 2004-10-28 2014-02-04 James W. Ogilvie Method of treating scoliosis using a biological implant
US20080305144A1 (en) * 2005-08-18 2008-12-11 Brown Malcolm Nmi High Strength Devices and Composites
CN100443065C (zh) * 2006-01-26 2008-12-17 上海交通大学 用于颌面骨缺损修复的复合体系植入体单元
AU2007325001B2 (en) 2006-11-30 2014-04-10 Smith & Nephew, Inc. Fiber reinforced composite material
AU2008240418B2 (en) 2007-04-18 2013-08-15 Smith & Nephew Plc Expansion moulding of shape memory polymers
JP5680957B2 (ja) 2007-04-19 2015-03-04 スミス アンド ネフュー インコーポレーテッドＳｍｉｔｈ ＆ Ｎｅｐｈｅｗ，Ｉｎｃ． グラフト固定
ATE547129T1 (de) 2007-04-19 2012-03-15 Smith & Nephew Inc Multimodale formgedächtnis-polymere
US8062739B2 (en) * 2007-08-31 2011-11-22 Zimmer, Inc. Hydrogels with gradient
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
EP2172189A1 (en) * 2008-10-01 2010-04-07 Novartis AG Pharmaceutical Compositions
WO2010018159A1 (en) 2008-08-12 2010-02-18 Novartis Ag Pharmaceutical compositions
US9642658B2 (en) 2008-10-15 2017-05-09 Orthoclip Llc Device and method for delivery of therapeutic agents via internal implants
EP2346421A1 (en) * 2008-10-15 2011-07-27 Bioshape Solutions Inc. Device and method for delivery of therapeutic agents via internal implants
BR112012002341A8 (pt) 2009-08-06 2017-10-10 Koninklijke Philips Electronics Nv Semente radioativa para uso na terapia oncológica e método de terapia oncológica
US20130071403A1 (en) 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
CN104189954B (zh) * 2014-09-19 2017-03-29 中国科学院长春应用化学研究所 一种原位固化组织工程支架及其制备方法
RU2571548C1 (ru) * 2014-12-17 2015-12-20 Федеральное государственное бюджетное учреждение науки Институт органической и физической химии им. А.Е. Арбузова Казанского научного центра Российской академии наук Ветеринарное имплантируемое средство пролонгированного действия (варианты)
CN108289844B (zh) 2015-11-16 2021-09-14 赢创运营有限公司 包含非核苷逆转录酶抑制剂和聚(丙交酯-共-乙交酯)的注射溶液
CN109498852B (zh) * 2018-12-29 2022-06-24 广州噢斯荣医药技术有限公司 治疗骨科疾病的生物降解材料及其应用
WO2021090146A1 (en) 2019-11-04 2021-05-14 Astrazeneca Ab Combination therapy for treating cancer
KR20230150790A (ko) 2020-12-29 2023-10-31 시노 메디칼 사이언시즈 테크놀로지, 인코포레이티드 약물 용출 스텐트
WO2024089417A1 (en) 2022-10-24 2024-05-02 Memorial Sloan-Kettering Cancer Center Tumour stratification for responsiveness to an immune checkpoint inhibitor
WO2024089418A1 (en) 2022-10-24 2024-05-02 Cancer Research Technology Limited Tumour sensitisation to checkpoint inhibitors with redox status modifier

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0754064B1 (en) * 1994-04-08 2003-05-28 Atrix Laboratories, Inc. An adjunctive polymer system for use with medical device
AU4652596A (en) 1995-01-09 1996-07-31 Atrix Laboratories, Inc. Liquid polymer delivery system
CA2275587C (en) * 1996-12-20 2006-10-24 Alza Corporation Injectable depot gel composition and method of preparing the composition
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US7128927B1 (en) * 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst

Also Published As

Publication number Publication date
GT200200242A (es) 2003-06-25
HUP0402135A2 (hu) 2005-02-28
JP2005515190A (ja) 2005-05-26
PL370085A1 (en) 2005-05-16
CN1599598A (zh) 2005-03-23
AU2002347502A1 (en) 2003-06-10
CA2468703A1 (en) 2003-06-05
TNSN04096A1 (fr) 2006-06-01
MXPA04003723A (es) 2005-04-08
ZA200402755B (en) 2005-04-08
HUP0402135A3 (en) 2008-04-28
KR20040062977A (ko) 2004-07-09
AU2009200125B2 (en) 2012-02-02
EP1448166A1 (en) 2004-08-25
WO2003045351A1 (en) 2003-06-05
GEP20063951B (en) 2006-10-25
YU35004A (sh) 2006-08-17
NO20042273L (no) 2004-07-14
DOP2002000534A (es) 2003-05-31
JP4903985B2 (ja) 2012-03-28
EA011350B1 (ru) 2009-02-27
KR100629380B1 (ko) 2006-09-29
BR0214610A (pt) 2004-09-14
ECSP045124A (es) 2004-07-23
AR037462A1 (es) 2004-11-10
PA8559001A1 (es) 2003-11-12
AP2004003037A0 (en) 2004-06-30
UA76792C2 (uk) 2006-09-15
IS7217A (is) 2004-04-07
EA200400608A1 (ru) 2004-10-28
AP1781A (en) 2007-09-27
NZ533115A (en) 2005-12-23
IL161835A0 (en) 2005-11-20
TW200300695A (en) 2003-06-16
US20090169595A1 (en) 2009-07-02
CA2468703C (en) 2009-12-29
US20030104031A1 (en) 2003-06-05
OA12731A (en) 2006-06-28
SV2004001421A (es) 2004-05-07
AU2009200125A1 (en) 2009-02-05
MA27084A1 (fr) 2004-12-20
HRP20040486A2 (en) 2004-10-31
US8017144B2 (en) 2011-09-13

Similar Documents

Publication Publication Date Title
PE20030581A1 (es) Composiciones polimeras de liberacion controlada de compuestos que promueven el crecimiento oseo
US20090016990A1 (en) Antimicrobial Compositions
JP2024028994A (ja) 抗菌組成物およびその使用
CA2513544C (en) An otorhinological delivery device
US20070020309A1 (en) Safe and effective biofilm inhibitory compounds and health related uses thereof
RS53890B1 (en) STABILIZED POLYMER DELIVERY SYSTEM
DK1780197T3 (da) 5-Substituerede 2-phenylamino-benzamider som MEK-inhibitorer
EP1089738A4 (en) ANTIMICROBIAL LOCKS COMPRISING DERIVATIVES OF TAURINAMIDE AND CARBOXYLIC ACIDS AND / OR THEIR SALTS
WO2014186937A1 (zh) 贻贝粘蛋白凝胶的制备方法、贻贝粘蛋白凝胶及其应用
MX2009003735A (es) Composicion en deposito inyectable y su procedimiento de preparacion.
KR20140037271A (ko) 유착 방지용 의료용 재료 및 그 제조 방법
JP2019030671A (ja) 薬物放出のための化合物及び組成物
WO2021023885A1 (en) Liquid dressing compositions and their uses
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
WO2007099302A8 (en) Methods of maintaining oral health in animals using morpholine derivatives
DE602005017581D1 (de) Verwendung von substituierten 1,2,3-indolizin-derivaten zur behandlung von krankheiten im zusammenhang mit einer pathologischen angiogenese
MX2009002260A (es) Cateter o desviacion implantable que permite el suministro gradual de agentes terapeuticos.
AR059071A1 (es) Metodos y composicionesque comprenden dextrano con peso molecular de 1 a 100 kda
RU2002117294A (ru) Применение буфера для профилактики кожных инфекций candida albicans
DE69930621D1 (de) Medizinische zusammensetzungen zur unmittelbaren freisetzung bei oraler anwendung
RU2426536C1 (ru) Способ профилактики спаечного процесса при повреждении сухожилий
WO2004032854A3 (en) Pharmaceutical compositions for treatment of parkinson's disease
TH63183A (th) สารผสมโพลีเมอริกควบคุมการปลดปล่อยของสารประกอบสนับสนุนการเจริญเติบโตของกระดูก
TH51768A (th) สารประกอบคาร์บาฟีเนม การใช้ของสารดังกล่าว และสารประกอบตัวกลางสำหรับสารดังกล่าว
ECSP003324A (es) Compuestos organicos

Legal Events

Date Code Title Description
FC Refusal